South Korea’s MFDS approved Curocell’s Rimqarto (anbal-cel; anbalcabtagene-autoleucel) as the first homegrown CAR T-cell therapy for advanced diffuse large B-cell lymphoma. The authorization marks a regulatory milestone for domestically developed autologous T-cell therapy and establishes a new commercial reference point for CD19-directed CAR T in the local market. Rimqarto becomes a key product for a rapidly evolving CAR-T landscape where next-generation designs and expanded indications are competing for clinician mindshare. The approval also raises attention on manufacturing scale, logistics, and patient selection protocols, which often determine real-world performance beyond clinical trial response. For Curocell, the immediate focus will be ramping clinical-to-commercial capacity and maintaining consistency in potency assays and release testing. For the broader ecosystem, MFDS approval is a signal that locally developed cell therapies can clear regulatory gates, potentially influencing how future sponsors structure development plans and in-country partnerships.